NCT06176027View on ClinicalTrials.gov

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions
Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Interventions
DRUG

Azacytidine plus CAOLD regimen

Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
collaborator

Chinese PLA General Hospital

OTHER

lead

Navy General Hospital, Beijing

OTHER